Paying user area
Try for free
AbbVie Inc. pages available for free this week:
- Common-Size Balance Sheet: Assets
- Analysis of Profitability Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Enterprise Value (EV)
- Price to FCFE (P/FCFE)
- Selected Financial Data since 2012
- Debt to Equity since 2012
- Price to Operating Profit (P/OP) since 2012
- Analysis of Debt
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to AbbVie Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
Operating profit margin | = | 100 | × | Operating earnings1 | ÷ | Net revenues1 | |
---|---|---|---|---|---|---|---|
Dec 31, 2024 | = | 100 | × | ÷ | |||
Dec 31, 2023 | = | 100 | × | ÷ | |||
Dec 31, 2022 | = | 100 | × | ÷ | |||
Dec 31, 2021 | = | 100 | × | ÷ | |||
Dec 31, 2020 | = | 100 | × | ÷ | |||
Dec 31, 2019 | = | 100 | × | ÷ | |||
Dec 31, 2018 | = | 100 | × | ÷ | |||
Dec 31, 2017 | = | 100 | × | ÷ | |||
Dec 31, 2016 | = | 100 | × | ÷ | |||
Dec 31, 2015 | = | 100 | × | ÷ | |||
Dec 31, 2014 | = | 100 | × | ÷ | |||
Dec 31, 2013 | = | 100 | × | ÷ | |||
Dec 31, 2012 | = | 100 | × | ÷ |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).
1 US$ in millions
The financial data reveals significant variations and several notable trends in key performance indicators over the analyzed period.
- Operating Earnings
- Operating earnings demonstrated considerable fluctuation through the years. After an initial decline from 2012 to 2014, there was a strong recovery peaking in 2019 with a value above 12 billion US dollars. Following this peak, earnings experienced a decline into 2024, with a pronounced reduction in 2024 relative to prior years. The volatility suggests periods of operational challenges and recovery.
- Net Revenues
- Net revenues exhibited a consistent upward trajectory across the entire period under review, increasing from approximately 18 billion US dollars in 2012 to over 56 billion US dollars by 2024. This sustained growth indicates successful revenue expansion, possibly through increased sales volume, pricing adjustments, or portfolio growth strategies.
- Operating Profit Margin
- The operating profit margin varied substantially, reflecting changes in profitability relative to revenues. Margins declined sharply in 2014 before rebounding in subsequent years, reaching the highest levels near 39% in 2019. However, after 2019, the margin showed a downward trend, ending at a lower level in 2024 compared to early years. This pattern aligns with fluctuations in operating earnings and may indicate varying cost structures or investment impacts.
Overall, while net revenues consistently increased, operating earnings and profit margins were more volatile. This suggests that while top-line growth was strong, profitability faced pressures from operational factors or cost management challenges during certain years.
Comparison to Competitors
AbbVie Inc. | Amgen Inc. | Danaher Corp. | Gilead Sciences Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
---|---|---|---|---|---|---|---|
Dec 31, 2024 | |||||||
Dec 31, 2023 | |||||||
Dec 31, 2022 | |||||||
Dec 31, 2021 | |||||||
Dec 31, 2020 | |||||||
Dec 31, 2019 | |||||||
Dec 31, 2018 | |||||||
Dec 31, 2017 | |||||||
Dec 31, 2016 | |||||||
Dec 31, 2015 | |||||||
Dec 31, 2014 | |||||||
Dec 31, 2013 | |||||||
Dec 31, 2012 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).